AI-generated analysis
myTomorrows' $29 million financing from Avego addresses a critical gap in global healthcare by expanding access to pre-approval treatments for patients worldwide. The investment bolsters myTomorrows’ AI-driven platform, which connects physicians and their patients with clinical trial sites and BioPharma partners to streamline treatment access. By leveraging advanced technology and personalized support services, the company aims to overcome barriers that prevent patients from accessing promising therapies still in development.
Avego’s expertise in life sciences will be crucial as myTomorrows scales its platform and deepens collaborations with industry stakeholders. The financing will enable the company to accelerate international growth, enhance real-world data capabilities, and shorten clinical development timelines for emerging treatments. This investment underscores myTomorrows’ strategic importance in bridging the gap between scientific advancements and patient access, particularly for underserved populations.
The deal shifts competitive dynamics by positioning myTomorrows as a leading facilitator of pre-approval treatment access. With over 16,900 patients supported across more than 133 countries, myTomorrows stands out in an evolving healthcare landscape where AI and data analytics are reshaping patient care. As regulatory frameworks adapt to accommodate new technologies, myTomorrows is well-positioned to capitalize on these changes through continued innovation and global expansion.
Post-close, key challenges include seamless integration of newly acquired resources and maintaining high operational efficiency while scaling operations internationally. Success will depend on the company’s ability to enhance its AI capabilities, expand partnerships, and continue delivering tailored solutions that address pressing healthcare needs. With Avego's backing, myTomorrows is poised for significant growth as it builds infrastructure critical for a new era of treatment access defined by adaptive regulation and empowered patient engagement.
myTomorrows, a Dutch health technology company connecting patients with pre-approval treatments, closed a $29 million financing round on November 11, 2025. The investment aims to accelerate the global expansion of myTomorrows' integrated pharmaceutical solutions and deepen industry partnerships.
| Acquirer | |
|---|
| Target | myTomorrows (NL) |
|---|
| Type | Financing |
|---|
| Value | $29 million |
|---|
| Close Date | November 11, 2025 |
|---|
| Announcement Date | November 11, 2025 |
|---|
| Buy-side financial advisors | Not disclosed |
|---|
| Sell-side financial advisors | Not disclosed |
|---|
| Legal advisors (buy) | Not disclosed |
|---|
| Legal advisors (sell) | Not disclosed |
|---|
Deal Mechanics:
The financing round aims to extend myTomorrows' reach, accelerate AI innovation and deepen industry partnerships. The funds will fuel the company's global expansion of integrated pharma solutions, making emerging treatments more equitable and accessible worldwide.
Strategic Rationale:
The investment marks a pivotal step in myTomorrows' journey to provide every patient with access to tomorrow’s therapies regardless of geographic location. Avego's extensive expertise in the life sciences sector will be instrumental as myTomorrows scales its platform and broadens its impact globally.
Financial Context:
Avego, founded in 2015 by former healthcare entrepreneurs, is a multi-strategy investment firm focused on innovative companies within the healthcare ecosystem. The company's diverse strategies include private equity, venture capital, and a long/short fund aimed at supporting both private and public firms developing new products and services for patients.
Outlook:
myTomorrows plans to use the investment to further develop its AI-driven global platform that connects physicians and their patients with trial sites and BioPharma partners. This will streamline access and insight, shortening clinical development timelines while enhancing real-world data capabilities for evidence generation.